Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Total Non-Current Liabilities: 2023-2024

Historic Total Non-Current Liabilities for Centessa Pharmaceuticals (CNTA) over the last 2 years, with Dec 2024 value amounting to $175.2 million.

  • Centessa Pharmaceuticals' Total Non-Current Liabilities rose 32.70% to $146.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.7 million, marking a year-over-year increase of 32.70%. This contributed to the annual value of $175.2 million for FY2024, which is 41.34% up from last year.
  • Latest data reveals that Centessa Pharmaceuticals reported Total Non-Current Liabilities of $175.2 million as of FY2024, which was up 41.34% from $124.0 million recorded in FY2023.
  • Centessa Pharmaceuticals' 5-year Total Non-Current Liabilities high stood at $175.2 million for FY2024, and its period low was $124.0 million during FY2023.
  • In the last 2 years, Centessa Pharmaceuticals' Total Non-Current Liabilities had a median value of $149.6 million in 2023 and averaged $149.6 million.
  • Data for Centessa Pharmaceuticals' Total Non-Current Liabilities shows a peak YoY skyrocketed of 41.34% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Centessa Pharmaceuticals' Total Non-Current Liabilities stood at $124.0 million in 2023, then skyrocketed by 41.34% to $175.2 million in 2024.